Week 96 Efficacy and Safety of Darunavir/Ritonavir Monotherapy vs. Darunavir/Ritonavir with Two Nucleoside Reverse Transcriptase Inhibitors in the PROTEA Trial

Pm Girard (1, 2) , A Antinori (3) , J. R. Arribas (4) , D Ripamonti , C Bicer (5) , B Netzle-Sveine (6) , B Hadacek (6) , C Moecklinghoff (6)

1 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique
2 CHU Saint-Antoine [AP-HP]
3 National Institute for Infectious Diseases "Lazzaro Spallanzani"
4 La Paz Hospital, IdiPAZ
5 Janssen Research & Development
6 Janssen EMEA

Domaines: Sciences du Vivant [q-bio]

Pm Girard, A Antinori, J. R. Arribas, D Ripamonti, C Bicer, et al.. Week 96 Efficacy and Safety of Darunavir/Ritonavir Monotherapy vs. Darunavir/Ritonavir with Two Nucleoside Reverse Transcriptase Inhibitors in the PROTEA Trial. HIV medicine, 2017, 18 (1), pp.5--12. ⟨10.1111/hiv.12386⟩. ⟨hal-03703933⟩